Myoclonic Cerebellar Dyssynergia

Myoclonic cerebellar dyssynergia is a rare neurodegenerative disorder characterized by myoclonus, cognitive impairment, epilepsy, and ataxia. Here is the latest research.

January 14, 2022

Movement disorders associated with neuronal antibodies: a data-driven approach.

Journal of Neurology
Andrea SturchioAlberto J Espay
January 11, 2022
Open Access

The Spectrum of Movement Disorders in Tertiary Care Centers in India: A Tale of Three Cities.

Annals of Indian Academy of Neurology
L K PrashanthUday Muthane
January 11, 2022
Open Access

Acute Ataxia and Myoclonus in COVID-19: A Case Series.

Annals of Indian Academy of Neurology
Uma S SundarDnyaneshwar C Asole
January 11, 2022
Case Report

Rarely fast progressive memory loss diagnosed as Creutzfeldt-Jakob disease: A case report.

World Journal of Clinical Cases
Yong-Wei XuYun-Xia Li
January 7, 2022

Clinical heterogeneity in patients with myoclonus associated to COVID-19.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Gary Álvarez BravoLluís Ramió I Torrentà
January 5, 2022

Lamotrigine-Associated Movement Disorder: A Literature Review.

Neurology India
Jamir Pitton Rissardo, Ana L Fornari Caprara
January 3, 2022

Postinfectious SARS-CoV-2 Opsoclonus-Myoclonus-Ataxia Syndrome.

Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
Jodi L NelsonJorge C Kattah
December 17, 2021

Relationship between COVID-19 and movement disorders: A narrative review.

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
Susanne A SchneiderDavide Martino
December 14, 2021
Open Access

Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma

BioRxiv : the Preprint Server for Biology
Miriam I RosenbergJ. M. Maris
December 14, 2021

Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report.

Therapeutic Advances in Neurological Disorders
Livia AsanMartin Köhrmann
December 14, 2021
Comment / Editorial

A diagnosis of progressive myoclonic ataxia guided by blood biomarkers: Expert commentary.

Parkinsonism & Related Disorders
L Pollini, Marina A J Tijssen
December 11, 2021

WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia.

Parkinsonism & Related Disorders
Matej SkorvanekRobert Jech
November 28, 2021
Case Report

Adult-onset rapidly worsening progressive myoclonic epilepsy caused by a novel variant in DHDDS.

Annals of Clinical and Translational Neurology
Seondeuk KimJangsup Moon
November 19, 2021
Open Access

Movement Disorders Associated with COVID-19.

Parkinson's Disease
Mehri SalariHosein Nouri

Sign up to follow this feed and discover related papers.

Related Feeds

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Endosomes

Dysfunctional endosomal trafficking may be associated with Alzheimer’s disease (AD) pathology. Targeting the endosome may advance treatment options for AD. Here is the latest research on endosomes and AD.

Alzheimer's Disease: Genetics

Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Alzheimer's Disease: Microglia

Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.

© 2022 Meta ULC. All rights reserved